Stockwinners Market Radar for August 07, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:02 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. CVS Health (CVS) is seeking to buy Signify Health (SGFY) as the drugstore and insurance giant looks to expand in home-health services, The Wall Street Journal's Cara Lombardo, Laura Cooper, and Sharon Terlep reported, citing people familiar with the matter. Signify Health is exploring strategic alternatives including a sale, The Wall Street Journal reported this past week. Initial bids are due this coming week and CVS is planning to enter one, some of the people said. Others also are in the mix, they said, and CVS could face competition from other managed-care providers and private-equity firms, the authors noted. 2. A group representing General Motors (GM), Toyota Motor (TM), Volkswagen (VWAGY) and other major automakers said a $430 billion bill approved Sunday by the U.S. Senate will put achieving U.S. electric-vehicle adoption targets for 2030 in jeopardy, Reuters' David Shepardson reported. "Unfortunately, the EV tax credit requirements will make most vehicles immediately ineligible for the incentive," said the Alliance for Automotive Innovation's chief executive, John Bozzella, adding the bill "will also jeopardize our collective target of 40%-50% electric vehicle sales by 2030." The group had warned Friday that most EV models would not qualify for a $7,500 tax credit for U.S. buyers under the bill. 3. Anyone who bought PayPal's (PYPL) stock last summer may be ruing the day, but set aside the wounds and buyer's remorse because PayPal deserves a second chance, Carleton English wrote in this week's edition of Barron's. The company is making operational changes and talking up financial discipline. Its core business remains solidly profitable, the author noted. At least one Wall Street activist likes the setup: Elliott Management. Known for its hardball tactics and takeover battles, Elliott recently took a 2% stake in PayPal, worth about $2 billion, the publication added. 4. Sony's (SONY) "Bullet Train" won the North American box office with an estimated weekend haul of $30.1M in its debut outing. Overseas, David Leitch's movie earned $32.4M for a global total of $62.4M. Brad Pitt leads the cast in this tale of an assassin roaming a high-speed bullet train. The film earned a B+ CinemaScore and holds a 53% critic's score on Rotten Tomatoes. 5. General Motors and Airbus (EADSY) saw positive mentions in this week's edition of Barron's.

14:49 EDT EQRx announces updated data from Phase 3 trial of Sugemalimab - EQRx announced a late-breaking oral presentation of updated data from the Phase 3 GEMSTONE-301 trial of sugemalimab in non-small cell lung cancer at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer. As of the March 2022 data cutoff, the final progression-free survival analysis of the Phase 3 GEMSTONE-301 trial showed that sugemalimab continued to demonstrate improvement in PFS compared to placebo as consolidation therapy for patients with locally advanced, unresectable Stage III NSCLC without disease progression after concurrent or sequential chemoradiotherapy. Median PFS was 10.5 months for sugemalimab and 6.2 months for placebo. PFS benefit was observed in the sugemalimab arm over the placebo arm regardless of whether patients received prior concurrent chemoradiotherapy or sequential chemoradiotherapy. The company said that data for overall survival, a secondary endpoint, were "encouraging but immature" at the time of the analysis. The safety profile for sugemalimab was consistent with previously reported results, and no new safety signals were identified within the follow-up period. GEMSTONE-301 previously met its PFS primary endpoint in May of 2021 and is the first positive Phase 3 trial of a PD-L1 agent in this Stage III NSCLC patient population setting.

12:01 EDT Musk says Twitter deal should not proceed if SEC filings 'materially false' - Tesla (TSLA) CEO Elon Musk said in a tweet Saturday, "If Twitter simply provides their method of sampling 100 accounts and how they're confirmed to be real, the deal should proceed on original terms. However, if it turns out that their SEC filings are materially false, then it should not." Musk added, "I hereby challenge @paraga to a public debate about the Twitter bot percentage. Let him prove to the public that Twitter has less than 5% fake or spam daily users!" The handle @paraga is Twitter (TWTR) CEO Parag Agrawal.